Taurine as a Possible Anti-aging Therapy?

December 2, 2021 updated by: Ellen Cristini de Freitas, University of Sao Paulo

Taurine as a Possible Anti-aging Therapy? A Controlled Clinical Trial on Taurine Antioxidant Activity in Women Aged 55 to 70 Years

Among the strategies that can improve the body's ability to counteract oxidative stress, the use of nutritional antioxidants has been investigated. Taurine is a "semi-essential" amino acid, also called a nitrogen compound, which has been used as an effective antioxidant due to its ability to neutralize hypochlorous acid, an extremely toxic oxidant produced by leukocytes in the inflammatory process in humans.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Objective: To evaluate the oxidative parameters of women aged 55 to 70 years after 16 weeks of taurine supplementation.

Methods: Twenty-four women age 55 to 70 will be randomly assigned to two groups: control group (GC), supplemented with placebo (1.5 g of starch); and taurine group (GTAU), supplemented with taurine (1.5 g), for 16 weeks. Anthropometry, functional capacity test, taurine, and levels of oxidative stress markers will be determined in pre and post intervention plasma samples. Food consumption will be assessed before, during, and after the intervention. The results will be analyzed by an ANOVA two-way repeated measures mixed model, with the Sidak post hoc (p < 0.05).

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • Sao Paulo
      • Ribeirao Preto, Sao Paulo, Brazil, 14040-907
        • Escola de Educação Física e Esporte de Ribeirão Preto

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Had being aged 55-70 years;
  • Female;
  • Post-menopausal;
  • Sedentary (not practicing physical exercise for at least 6 months).

Exclusion Criteria:

  • Chronic kidney diseases;
  • Infectious contagious diseases;
  • Coronary heart disease;
  • Smokers
  • Alcoholics.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Taurine supplementation
Taurine supplementation composed of capsules of taurine powder. Dosage: 1.5 gram/day Frequency: 1 time/day Duration: 16 weeks
Dietary supplement: Taurine
Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
Other Names:
  • Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 grams/day
PLACEBO_COMPARATOR: Placebo supplementation
Placebo supplementation composed of capsules of starch powder. Dosage: 1.5 gram/day Frequency: 1 time/day Duration: 16 weeks
Dietary supplement: Placebo
Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in blood oxidative stress marker measurement - Superoxide Dismutase (SOD).
Time Frame: sixteen weeks
The superoxide dismutase (SOD) activity in erythrocytes was evaluated by the spectrophotometric method, and were calculated at 16 weeks in comparision to the baseline.
sixteen weeks
Change from baseline in blood oxidative stress marker measurement - Glutathione reductase (GR).
Time Frame: sixteen weeks
Glutathione reductase (GR) activity was determined by the spectrophotometric method at 37 ºC/340nm after the oxidation of NADPH in the presence of oxidized glutathione, and were calculated at 16 weeks in comparision to the baseline.
sixteen weeks
Change from baseline in blood oxidative stress marker measurement - Malondialdehyde (MDA).
Time Frame: sixteen weeks
The malondialdehyde (MDA) were calculated at 16 weeks in comparision to the baseline.
sixteen weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Sao Paulo

Collaborators

Fundação de Amparo à Pesquisa do Estado de São Paulo
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 13, 2020

Primary Completion (ACTUAL)

June 15, 2020

Study Completion (ACTUAL)

July 3, 2020

Study Registration Dates

First Submitted

November 19, 2021

First Submitted That Met QC Criteria

December 2, 2021

First Posted (ACTUAL)

December 8, 2021

Study Record Updates

Last Update Posted (ACTUAL)

December 8, 2021

Last Update Submitted That Met QC Criteria

December 2, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • Taurine_aging

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Oxidative Stress

Clinical Trials on Taurine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe